Skip to main content

Onconic Therapeutics (476060.KQ)

58.1Fair

ValueMarkers Composite Index

Top 69%#13,878 of 44,722

DCF data not available

Piotroski
5/9
Neutral
Beneish
0.50
High Risk
Altman
41.00
Safe
DCF Value
-
N/A
ROIC
17.5%
Strong
P/E
63.0
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Onconic Therapeutics (476060.KQ) — VMCI valuation read

The headline on Onconic Therapeutics (476060.KQ) is a 58/100 VMCI score, set against a Healthcare sector median of 50. That 8-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

476060.KQ insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** 476060.KQ trades at 23.0x earnings, 28% above the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 3.5x is the binding constraint on the bear case sets the risk side, the three lines a value buyer reads first on 476060.KQ.

476060.KQ rose 1.0% over the trailing 7 days, with a -16.0% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.